Stay updated with breaking news from Lynnc Headrick. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Abbott (NYSE: ABT) today announced that the U.S. Food and Drug Administration (FDA) has approved the company's first-of-its-kind TriClip™ transcatheter edge-to-edge repair (TEER) system that's specifically designed for the treatment of tricuspid regurgitation (TR), or a leaky tricuspid valve. This approval follows ...
Less than 2 months after being the subject of an FDA AdComm meeting, Abbott's TriClip TEER System has received approval for tricuspid regurgitation.
Abbott has announced U.S Food and Drug Administration (FDA) approval of its TriClip, a first-of-its-kind device to repair leaky tricuspid heart valve, for which more than 1.6 million people in the U.S. are estimated to be affected. Data from the TRILUMINATE Pivotal trial demonstrated that patients who received TriClip experienced a marked improvement in the severity of their symptoms and quality of life, with benefits sustained at one year.
Abbott (NYSE: ABT) announced that the FDA granted approval for its first-of-ts-kind TriClip transcatheter edge-to-edge repair (TEER) system.
BRISBANE, CALIFORNIA, Aug. 03, 2023 -- GT Biopharma, Inc. , a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary natural killer ...